Antibody tests have been heralded as a crucial weapon in the battle against the Covid-19 pandemic. Although these tests are essential to helping epidemiologists better understand the disease and how it spreads, the precise antibodies developed against Covid-19 are also invaluable in discovering therapies to treat patients.

Berkeley Lights CEO Eric Hobbs notes it is going to take a while for vaccines to be approved, but “in the meantime, there is something that will help [tackle Covid-19]: antibody therapeutics.” Hobbs discusses how his company’s Beacon platform can support the development of these drugs against Covid-19, as well as future emerging pathogens.

Read the full story here.